Advertisement

Current Hepatitis Reports

, Volume 6, Issue 2, pp 39–45 | Cite as

The impact of steatosis and alcohol on hepatitis C

  • Sam Galhenage
  • Manal F. AbdelmalekEmail author
Article
  • 25 Downloads

Abstract

Alcohol consumption and hepatic steatosis interact synergistically with hepatitis C virus (HCV) to accelerate fibrosis progression and reduce the efficacy of standard antiviral therapies. Research aimed at delineating the viral and host interactions involved in the pathogenesis of steatosis in HCV infection may provide novel therapeutic strategies that can modify disease progression and improve treatment response. This review discusses the clinical aspects of HCV fibrosis progression and treatment response in the setting of alcohol use or hepatic steatosis.

Keywords

Chronic Hepatitis NASH Antiviral Therapy Hepatic Steatosis Nonalcoholic Fatty Liver Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Poynard T, Ratziu V, McHutchison J, et al.: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Adinolfi LE, Gambardella M, Adreana A, et al.: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358–1364.PubMedCrossRefGoogle Scholar
  3. 3.
    Ohata K, Hamasaki K, Toriyanna K, et al.: Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with mild hepatitis C. Hepatology 2004, 41:82–87.CrossRefGoogle Scholar
  4. 4.
    Caetano R, Laranjeira R: A “perfect storm” in developing countries: economic growth and the alcohol industry. Addiction 2006, 101:149–152.PubMedCrossRefGoogle Scholar
  5. 5.
    Haslam D, Sattar N, Lean M: ABC of obesity. Obesity—time to wake up [review]. BMJ 2006, 333:640–642.PubMedCrossRefGoogle Scholar
  6. 6.
    Morrison DS, Boyd AA, Richardson T: Liver cirrhosis mortality rates in Britain [letter]. Lancet 2006, 367:1899.PubMedCrossRefGoogle Scholar
  7. 7.
    Adams LA, Sanderson S, Lindor KD, et al.: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005, 42:132–138.PubMedCrossRefGoogle Scholar
  8. 8.
    Browning JD, Szczepaniak LS, Dobbins R, et al.: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387–1395.PubMedCrossRefGoogle Scholar
  9. 9.
    Degos F: Hepatitis C and alcohol. J Hepatol 1999, 31(Suppl 1):113–118.PubMedCrossRefGoogle Scholar
  10. 10.
    Wiley TE, McCarthy M, Breidi L, et al.: Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998, 28:805–809.PubMedCrossRefGoogle Scholar
  11. 11.
    Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825–832.PubMedCrossRefGoogle Scholar
  12. 12.
    Marrero JA, Fontana RJ, Fu S, et al.: Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005, 42:218–224.PubMedCrossRefGoogle Scholar
  13. 13.
    National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10–12, 2002). Gastroenterology 2002, 123:2082–2099.CrossRefGoogle Scholar
  14. 14.
    Ostapowicz G, Watson KJ, Locarnini SA, et al.: Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998, 27:1730–1735.PubMedCrossRefGoogle Scholar
  15. 15.
    Morgan TR, Mandayam S, Jamal MM: Alcohol and hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1):S87–S96.PubMedCrossRefGoogle Scholar
  16. 16.
    Massard J, Ratziu V, Thabut D, et al.: Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006, 44(1 Suppl):S19–S24.PubMedCrossRefGoogle Scholar
  17. 17.
    Niederau C, Lange S, Heintges T, et al.: Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998, 28:1687–1695.PubMedCrossRefGoogle Scholar
  18. 18.
    Hezode C, Lonjon I, Roudot-Thoraval F, et al.: Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 2003, 17:1031–1037.PubMedCrossRefGoogle Scholar
  19. 19.
    Bellentani S, Pozzato G, Saccoccio G, et al.: Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999, 44:874–880.PubMedGoogle Scholar
  20. 20.
    Harris HE, Ramsay ME, Andrews N, et al.: Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002, 324:450–453.PubMedCrossRefGoogle Scholar
  21. 21.
    Loguercio C, Di Pierro M, Di Marino MP, et al.: Drinking habits of subjects with hepatitis C virus related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol 2000, 35:296–301.PubMedGoogle Scholar
  22. 22.
    Romero-Gomez M, Grande L, Nogales MC, et al.: Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. Dig Liver Dis 2001, 33:698–702.PubMedCrossRefGoogle Scholar
  23. 23.
    Anand BS, Thornby J: Alcohol has no effect on hepatitis C virus replication: a meta-analysis. Gut 2005, 54:1468–1472.PubMedCrossRefGoogle Scholar
  24. 24.
    Manolakopoulos S, Economou M, Bethanis S, et al.: A single alcohol ingestion does not affect serum hepatitis C virus RNA in patients with chronic hepatitis C. Liver Int 2006, 26:1196–1200.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang T, Li Y, Lai JP, et al.: Alcohol potentiates hepatitis C virus replicon expression. Hepatology 2003, 38:57–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Szabo G, Aloman C, Polyak SJ, et al.: Hepatitis C infection and alcohol use: a dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res 2006, 30:709–719.PubMedCrossRefGoogle Scholar
  27. 27.
    Rigamonti C, Mottaran E, Reale E, et al.: Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 2003, 38:42–49.PubMedCrossRefGoogle Scholar
  28. 28.
    Bailey SM, Cunningham CC: Contribution of mitochondria to oxidative stress associated with alcoholic liver disease. Free Radic Biol Med 2002, 32:11–16.PubMedCrossRefGoogle Scholar
  29. 29.
    Valgimigli M, Valgimigli L, Trere D, et al.: Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. Free Radic Res 2002, 36:939–948.PubMedCrossRefGoogle Scholar
  30. 30.
    Tilg H, Diehl AM: Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343:1467–1476.PubMedCrossRefGoogle Scholar
  31. 31.
    Plumlee CR, Lazaro CA, Fausto N, Polyak SJ: Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells. Virol J 2005, 2:89.PubMedCrossRefGoogle Scholar
  32. 32.
    Pessione F, Degos F, Marcellin P, et al.: Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998, 27:1717–1722.PubMedCrossRefGoogle Scholar
  33. 33.
    Ohnishi K, Matsuo S, Matsutani K, et al.: Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996, 91:1374–1379.PubMedGoogle Scholar
  34. 34.
    Tabone M, Sidoli L, Laudi C, et al.: Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 2002, 9:288–294.PubMedCrossRefGoogle Scholar
  35. 35.
    Anand BS, Currie S, Dieperink E, et al.: Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006, 130:1607–1616.PubMedCrossRefGoogle Scholar
  36. 36.
    Clark JM: The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40(3 Suppl 1):S5–S10.PubMedGoogle Scholar
  37. 37.
    Matos CA, Perez RM, Pacheco MS, et al.: Steatosis in chronic hepatitis C: relationship to the virus and host risk factors. J Gastroenterol Hepatol 2006, 21:1236–1239.PubMedCrossRefGoogle Scholar
  38. 38.
    Castera L, Chouteau P, Hezode C, et al.: Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol 2005, 100:711–715.PubMedCrossRefGoogle Scholar
  39. 39.
    Moriya K, Shintani Y, Fujie H, et al.: Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res 2003, 25:369–374.Google Scholar
  40. 40.
    Castera L, Hezode C, Roudot-Thoraval F, et al.: Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004, 53:420–424.PubMedCrossRefGoogle Scholar
  41. 41.
    Collier JD, Woodall T, Wight DG, et al.: Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection. J Viral Hepat 2005, 12:74–80.PubMedCrossRefGoogle Scholar
  42. 42.
    Patton HM, Patel K, Behling C, et al.: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484–490.PubMedCrossRefGoogle Scholar
  43. 43.
    Cholet F, Nousbaum JB, Richecoeur M, et al.: Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol 2004, 28:272–278.PubMedCrossRefGoogle Scholar
  44. 44.
    Hui JM, Kench J, Farrell GC, et al.: Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002, 17:873–881.PubMedCrossRefGoogle Scholar
  45. 45.
    Asselah T, Boyer N, Guimont MC, et al.: Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003, 52:1638–1643.PubMedCrossRefGoogle Scholar
  46. 46.
    Freeman AJ, Dore GJ, Law MG, et al.: Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001, 34:809–816.PubMedCrossRefGoogle Scholar
  47. 47.
    Fartoux L, Chazouilleres O, Wendum D, et al.: Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005, 41:82–87.PubMedCrossRefGoogle Scholar
  48. 48.
    Adinolfi LE, Gambardella M, Andreana A, et al.: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358–1364.PubMedCrossRefGoogle Scholar
  49. 49.
    Camma C, Bruno S, Di Marco V, et al.: Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006, 43:64–71.PubMedCrossRefGoogle Scholar
  50. 50.
    Powell EE, Jonsson JR, Clouston AD: Steatosis: co-factor in other liver diseases. Hepatology 2005, 42:5–13.PubMedCrossRefGoogle Scholar
  51. 51.
    Rubbia-Brandt L, Fabris P, Paganin S, et al.: Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004, 53:406–412.PubMedCrossRefGoogle Scholar
  52. 52.
    Westin J, Nordlinder H, Lagging M, et al.: Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002, 37:837–842.PubMedCrossRefGoogle Scholar
  53. 53.
    Leandro G, Mangia A, Hui J, et al.: Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006, 130:1636–1642.PubMedCrossRefGoogle Scholar
  54. 54.
    Younossi ZM, McCullough AJ, Ong JP, et al.: Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004, 38:705–709.PubMedCrossRefGoogle Scholar
  55. 55.
    Clouston AD, Jonsson JR, Purdie DM, et al.: Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001, 34:314–320.PubMedCrossRefGoogle Scholar
  56. 56.
    Fartoux L, Poujol-Robert A, Guechot J, et al.: Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005, 54:1003–1008.PubMedCrossRefGoogle Scholar
  57. 57.
    Hickman IJ, Powell EE, Prins JB, et al.: In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003, 39:1042–1048.PubMedCrossRefGoogle Scholar
  58. 58.
    McCaughan GW, George J: Fibrosis progression in chronic hepatitis C virus infection. Gut 2004, 53:318–321.PubMedCrossRefGoogle Scholar
  59. 59.
    Ohata K, Hamasaki K, Toriyama K, et al.: Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97:3036–3043.PubMedCrossRefGoogle Scholar
  60. 60.
    Kumar D, Farrell GC, Kench J, et al.: Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol 2005, 20:1395–1400.PubMedCrossRefGoogle Scholar
  61. 61.
    Durante-Mangoni E, Zampino R, Marrone A, et al.: Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006, 24:1349–1357.PubMedCrossRefGoogle Scholar
  62. 62.
    Maeno T, Okumura A, Ishikawa T, et al.: Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2003, 18:1358–1363.PubMedCrossRefGoogle Scholar
  63. 63.
    Koike K: Hepatitis C virus infection can present with metabolic disease by inducing insulin resistance. Intervirology 2006, 49:51–57.PubMedCrossRefGoogle Scholar
  64. 64.
    Sanyal AJ, Chand N, Comar K, et al.: Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic fatty liver disease [abstract]. Hepatology 2004, 40(Issue S4):179A (Abstract 39).Google Scholar
  65. 65.
    Westin J, Lagging M, Dhillon AP, et al.: Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007, 14:29–35.PubMedCrossRefGoogle Scholar
  66. 66.
    Charlton MR, Pockros PJ, Harrison SA: Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006, 43:1177–1186.PubMedCrossRefGoogle Scholar
  67. 67.
    Tarantino G, Conca P, Sorrentino P, et al.: Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 2006, 21:1266–1268.PubMedCrossRefGoogle Scholar
  68. 68.
    Conjeevaram HS, Kleiner DE, Everhart JE, et al.: Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007, 45:80–87.PubMedCrossRefGoogle Scholar
  69. 69.
    Hickman IJ, Jonsson JR, Prins JB, et al.: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53:413–419.PubMedCrossRefGoogle Scholar
  70. 70.
    Bastard JP, Maachi M, Lagathu C, et al.: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4–12.PubMedGoogle Scholar
  71. 71.
    Belfort R, Harrison SA, Brown K, et al.: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297–2307.PubMedCrossRefGoogle Scholar
  72. 72.
    Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al.: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008–1017.PubMedGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2007

Authors and Affiliations

  1. 1.Division of Gastroenterology, Hepatology & NutritionDuke University Medical CenterDurhamUSA

Personalised recommendations